Sustainable Health Services · Horlicks 25 g serving 125 g CO 2 eq. per serving - 0.0500 0.1000...

www.sdu.nhs.uk www.sdu.nhs.uk

London November 2012

Sustainable Health Services


(John Schaar)

“The future is not a result

of choices among

alternative paths offered by

the present,

but a place that is created

- first in the mind and will,

next in activity.”

The world’s leading sustainability consultancy

Product Comparisons and the Need for Product Rules

Tom Penny Senior Consultant 30th November 2012


A management tool! ■ Measure, manage and reduce

■ Covers all products in sector

■ Internal product appraisals

■ Hotspot analysis

■ Target reductions

■ Eco-design initiatives

■ Track and report performance over time

■ Public reporting

vs

What the Sector Guidance Does (and Doesn’t Do)

7

Guidance is not specific enough to support external comparative assertions between similar products


Need for Product Rules

8

To support:

■ Product labelling

■ Performance claims

■ Quantitative procurement/prescription decisions

■ Best developed for products where there is a choice and the opportunity to achieve significant GHG benefits is significant


What Product Rules Need to Address

9

To allow accurate comparisons guidance needs to be made into rules

Same issues as sector guidance but more specific to product groups:

■ Functionality & unit of analysis

■ Boundaries of system appraised

■ Allocation methods

■ Data requirements

Must be prescriptive but fair

Product Rules are required to achieve meaningful comparisons


GHG Protocol Product Standard

10

GHG

Protocol

Product

Standard

Sector

Guidance

Product

Rules

Consistent

Product

Comparisons

■ Sector guidance: offers a route to assist sectors in completing product carbon footprints

■ Product rules: provide additional specifications that enable valid

comparisons of two or more products to be made

Two types of supplementary documents described:


How Product Rules are Developed

11

Stakeholder group is assembled to develop product rule ■ Affected parties

■ Diverse with relevant expertise

Public consultation process and road testing phase

Peer review is undertaken ■ Conform to GHG Protocol

■ Possible to gain the ‘Built on GHG Protocol’ through review by GHG Protocol

Additional considerations ■ There are safeguards in place to prevent conflict of interest

■ The product rules are developed to have an international reach

■ A process for regular review and updates is in place


Where to Start?

12

Consider which products would benefit from more specific guidance

■ High sales volume

■ Products with significant GHG emissions

■ Where meaningful functional comparisons exist

■ Where claims are currently being made

Where healthcare sector and companies want to differentiate between product choices

Where they can make a difference!


About ERM ERM is one of the leading sustainability consultants worldwide, providing environmental, health and safety, risk and social consulting services in influential assignments. Over 3600 employees globally in 40 countries. Over the past five years we have worked for approximately 60% of the Global Fortune 500. 39 years of experience in the field with in-depth subject matter and sector experience.

Who to talk to at ERM:

Tom Penny

Senior Consultant

+44 (0) 203 206 5386

[email protected]

GSK: Role of carbon footprinting November 2012

Who we are and what we do We are a science-led global healthcare company. We make innovative medicines, vaccines, and consumer healthcare products used by millions of people worldwide. Our products contribute directly to the health of patients and consumers, and indirectly to the wider well-being of the economy and society. We are committed to generating sustainable performance and returns for shareholders in a responsible way. To improve the quality of human life by enabling people to Do More, Feel Better, Live Longer

What we do

We research and develop a broad range of innovative products. We have three primary business areas:

Pharmaceuticals Vaccines Consumer Healthcare

We develop and make available

medicines to treat a broad range of serious and chronic diseases.

£18.7bn Turnover

68% of group

We research and make vaccines for children and adults that protect against infectious disease.

£3.5bn Turnover

13% of group

We make a range of innovative consumer health products in four global categories of Wellness, Skin Health, Oral Health and Nutrition.

£5.2bn Turnover

19% of group

£27.4bn group sales

GSK High Level Environmental Sustainability Strategy –

Carbon Neutral Value Chain by 2050

2020 2015

5.6 million mt CO2 eq. 0.2 million mt CO2 eq. ? 2.6 million mt CO2 eq.

MATERIALS OPERATIONS DISTRIBUTION USE END OF LIFE

GSK Environmental Strategy

PROPELLANTS

5.2 million mt CO2 eq. <1%

GSK Value Chain Carbon Footprint is 14 million mt CO2 eq. per annum

10% reduction in overall

Carbon Footprint

25% reduction in overall

Carbon Footprint

20% reduction

(Direct Ops)

20% reduction

(Value Chain)

• 2.5% Mass efficiency

• 25% Reduction in Operational

waste to landfill

• 25% Reduction in hazardous

and non-hazardous waste

• 5% Mass efficiency

• Zero Operational waste to landfill

• 50% Reduction in hazardous and

non-hazardous waste

Our planet – Product Footprinting

Growing our business while protecting the natural resources we all need for the future

MDI 200 actuation device

293 g CO2 eq. per actuation

DPI 60 dose device

16 g CO2 eq. per dose

Current mode of disposal for asthma inhaler

Q3A. How do you currently dispose of your/your child’s asthma inhaler device when you

have finished using it?

Base: All respondents (503) Survey performed by Kantar Health

Put it in the

domestic

waste bin at

home

63%

23% Put it in the recycling bin at home 11%

Take to a pharmacy that offers a recycling service

Other mentions ≤ 10%

Consumer Healthcare

Our planet case study – reducing emissions from our inhalers

Around 40% of our carbon footprint comes from

propellants released from our inhalers.

Any inhaler not just GSK

New ways of managing manufacturing waste

Pharma distribution supplier: no extra trips needed,

used to handling medicines, good tracking processes

and willingness to partner

Pharmacist:Patient interactions

Many being returned full or partially full

Worked with supplier to use recycled aluminium

(9ktCO2e saved)

Complete the Cycle progress

Our planet – Product Footprinting

Growing our business while protecting the natural resources we all need for the future

Horlicks 25 g serving

125 g CO2 eq. per serving

-

0.0500

0.1000

0.1500

0.2000

0.2500

0.3000

0.3500

0.4000

0.4500

Form Raw Mats

Pack Raw Mats Energy Transport Waste

GSK UK

GSK India

Footprint pattern quite different

Milk supply is key

20,000+ farmers

Cattle Development Centres

Switching from coal to biomass

MDI 200 actuation device

293 g CO2 eq. per actuation

DPI 60 dose device

16 g CO2 eq. per dose

Benefits of footprinting

Better understand of whole value chain

Identify hotspots, risks, threats, opportunities

Prioritisation (which products, stages etc.)

Involves the whole business and suppliers

Robust/standard approach

Comparison (between identical molecules)

Help with future product strategies

Aligns with customer (NHS, Tesco, Walmart...)

Country business unit footprints


Any Questions? .


Focus Groups

• Topic 1: how should the guidance be taken

forward?

-What actions can group members take to

facilitate this?

• Topic 2: what 3 future projects could facilitate

pharmaceutical and medical device use as part of

sustainable healthcare pathways?

- What actions can group members take to

facilitate this?


Thank you

Sustainable Health Services · Horlicks 25 g serving 125 g CO 2 eq. per serving - 0.0500 0.1000...

Documents

Transcript of Sustainable Health Services · Horlicks 25 g serving 125 g CO 2 eq. per serving - 0.0500 0.1000...